Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Biesecker Lab/Clinical Genomics Section, |
RCV000172242 | SCV000054924 | uncertain significance | not provided | 2013-06-24 | criteria provided, single submitter | research | |
Eurofins Ntd Llc |
RCV000172242 | SCV000855297 | uncertain significance | not provided | 2017-11-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002345593 | SCV002642792 | uncertain significance | Cardiovascular phenotype | 2020-02-14 | criteria provided, single submitter | clinical testing | The p.R17948Q variant (also known as c.53843G>A), located in coding exon 153 of the TTN gene, results from a G to A substitution at nucleotide position 53843. The arginine at codon 17948 is replaced by glutamine, an amino acid with highly similar properties. This variant (referred to as p.R27013Q) co-occurred with a TTN frameshift variant in an individual from a dilated cardiomyopathy cohort (Minoche AE et al. Genet. Med., 2019 03;21:650-662). This variant (referred to as p.R24445Q) has also been reported as a secondary cardiac variant in an exome cohort (Ng D et al. Circ Cardiovasc Genet, 2013 Aug;6:337-46). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000172242 | SCV003819701 | uncertain significance | not provided | 2019-03-03 | criteria provided, single submitter | clinical testing |